Back to Search Start Over

Assessing solubility of meloxicam in age-specific gastric and intestinal media relevant to adults and pediatric populations: implications for optimizing dosing in patients for postoperative pain.

Authors :
Omar SA
Nairat R
Khzimia S
Maqboul I
Jaber M
Shawahna R
Source :
BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2024 Oct 09; Vol. 25 (1), pp. 75. Date of Electronic Publication: 2024 Oct 09.
Publication Year :
2024

Abstract

Background: Oral dose formulations must be soluble in gastrointestinal fluids for systemic absorption. The solubility of meloxicam was determined in 16 different age-specific simulated gastric and intestinal media that mirrored the microenvironments in pediatrics and adults.<br />Methods: The solubility of meloxicam in the 16 different age-specific simulated gastric and intestinal biorelevant media was assessed using the standard US pharmacopeial method. The molecular descriptors of meloxicam were used to assess its intestinal permeability.<br />Results: Meloxicam exhibited low solubility in the age-specific simulated gastric media for fasted and fed states and in pediatrics and adults. Similarly, meloxicam exhibited low solubility in the age-specific simulated media that mirrored neonates fed cow milk-based formula. On the other hand, meloxicam exhibited high solubility in the rest of the age-specific pediatric and adult intestinal media that simulated the fasted and fed states. The pediatric-to-adult solubility ratios were outside the 80-125% range in 7 (58.3%) and was borderline in 1 (8.3%) out of the 12 calculated ratios. These findings indicated that the solubility of meloxicam showed clinically significant differences in 8 (66.7%) of the compared media.<br />Conclusion: Meloxicam exhibited low solubility in the age-specific simulated gastric media and high solubility in the simulated intestinal media for adults and pediatrics. Moreover, the pediatric-to-adult solubility ratios may have clinically significant implications. These differences can be translated into a higher likelihood of failing to demonstrate bioequivalence of different formulations containing meloxicam and variabilities in the performance of these formulations.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2050-6511
Volume :
25
Issue :
1
Database :
MEDLINE
Journal :
BMC pharmacology & toxicology
Publication Type :
Academic Journal
Accession number :
39385231
Full Text :
https://doi.org/10.1186/s40360-024-00799-7